Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.
about
The role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationBone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adultsBone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for haematological malignanciesThe role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationPolyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsPolyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell/bone marrow transplantationMicrobiome mediation of infections in the cancer settingTrial Watch: Adoptive cell transfer for oncological indicationsThe complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activityNanoparticle-based monitoring of cell therapy.Harnessing immunosurveillance: current developments and future directions in cancer immunotherapyDanger Signals and Graft-versus-host Disease: Current Understanding and Future PerspectivesImproving cell-based therapies by nanomodificationGenetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progressionBusulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthaseThe indications for allogeneic stem cell transplantation in myeloid malignancies.Acoustophoretic sorting of viable mammalian cells in a microfluidic deviceWnt7a stimulates myogenic stem cell motility and engraftment resulting in improved muscle strength.Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activityHeat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice.The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success.Stem cells and regenerative medicine: accomplishments to date and future promise.Autophagy gene Atg16L1 prevents lethal T cell alloreactivity mediated by dendritic cells.Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantationEnhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials.Classification of current anticancer immunotherapiesImpaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosissiRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients.Haematological malignancies: at the forefront of immunotherapeutic innovation.Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease.Hematopoietic derived cell infiltration of the intestinal tumor microenvironment in Apc Min/+ mice.Influence of donor microbiota on the severity of experimental graft-versus-host-disease.Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice.The central nervous system is a target of acute graft versus host disease in mice.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Generation of anterior foregut endoderm from human embryonic and induced pluripotent stem cells.
P2860
Q24186279-95046648-AC6B-4C7D-BDC5-DD23800FFFC5Q24195048-E6A53043-D903-4ED7-A0BB-D5EADA95157AQ24197741-BB30D1D7-F8E3-43F6-843D-39FF874D28DFQ24198004-7D6B1966-BAF6-4CEF-A687-451C7D25CB0BQ24200813-AEE030AB-CFF7-4D46-A393-0F9DE4039860Q24234072-8464112E-2359-4C6C-ABA9-4311EC89ACA1Q26752672-F08DE816-87C5-4CD5-B2C8-3CB232BF654CQ26785545-FB7FB9F3-CE9D-4C76-875A-4116FDE1335FQ26851545-828057D3-6A2C-4830-B90B-620A88E14DAFQ27000646-366D6D15-B53D-4713-B098-0D9284AFF8B2Q27021570-427E2BE5-171D-45B3-9786-51B71014CF3CQ28075204-518846FD-6B53-41E5-B056-C7C1C649DE81Q28080427-2CE86C38-3B14-4C21-9125-C1DCB6EB770DQ28304978-08DB1CF8-1D3B-4A50-B51D-8B4DA05B64E6Q28732371-445E82A1-2471-4E2A-A652-602E7C31558BQ30316611-50E314B8-1E22-4D7D-B02D-D250AB992F9DQ30453395-8E0FDCDF-3A4D-4A1A-9B1C-EFC44EBAFDFEQ30576111-C8FDA216-3E2E-4E4E-A2D8-12A643DDE630Q33394689-DE5D6D6C-824C-4BEC-B408-A24A30EE05DBQ33573863-40F2A330-6C16-4475-8B5C-00C26F7D6467Q33585305-E43426CD-4322-48AB-8003-02221F8F5398Q33724352-8B3006EA-FE82-475C-B1F9-07295E044202Q34343825-C6B886FE-A285-4C7D-8781-B09155B9A94CQ34541457-9E8DE9E6-ED16-4278-ADE8-5BC39CCA2FF6Q34580132-5E1EA682-FFB2-449E-9837-E76C8F13D72AQ34973719-FAA9E374-B59C-45E0-9710-F028F36035B4Q35142623-7558D3A7-2A58-4336-BE89-EDA64B48389EQ35149637-E2ADEA04-375F-457F-844C-E43D4909C133Q35250694-F1F378AD-A015-4D81-A61E-7CDDD01F13E6Q35546869-8E50C753-A62F-4CC4-9430-2A430C0381CCQ35738506-16BE916F-E336-43C2-8AF2-2DB894F5B563Q35812995-2992A952-F7D0-4861-952C-3E6898B6D08EQ35880618-EB4D0E92-FFB4-4DB3-9B7A-A4E6B2E11D08Q35964585-07A33540-A139-4AE0-9522-D3906A8954AFQ35996855-AF90D62C-A5EB-4D93-9967-D5A83B9ACF14Q36487338-9C1E30B9-BD8A-4F91-AEB6-2B76B83E28D2Q36572920-909ACD8D-8105-4044-8F4D-DE6A10A72D59Q36666826-9880941B-AEFD-4ABF-9996-3192D232AB0CQ36887833-D837FAE1-D2C7-43DB-8BF2-7F85222C1F5DQ36901227-F55CD188-359E-4631-B4D4-3FFC473D02C1
P2860
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Allogeneic haematopoietic stem ...... and immune therapy of cancer.
@en
Allogeneic haematopoietic stem ...... and immune therapy of cancer.
@nl
type
label
Allogeneic haematopoietic stem ...... and immune therapy of cancer.
@en
Allogeneic haematopoietic stem ...... and immune therapy of cancer.
@nl
prefLabel
Allogeneic haematopoietic stem ...... and immune therapy of cancer.
@en
Allogeneic haematopoietic stem ...... and immune therapy of cancer.
@nl
P2860
P356
P1476
Allogeneic haematopoietic stem ...... and immune therapy of cancer.
@en
P2093
Marcel R M van den Brink
Robert R Jenq
P2860
P2888
P304
P356
10.1038/NRC2804
P407
P577
2010-02-19T00:00:00Z